*NO COVER LETTER

IPOS COPY 9802240-3

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/41, C07D 257/04

A1

(11) International Publication Number: WO 97/10822

(43) International Publication Date: 27 March 1997 (27.03.97)

(21) International Application Number: PCT/US96/15103

(22) International Filing Date: 20 September 1996 (20.09.96)

(30) Priority Data:
60/004,083 21 September 1995 (21.09.95) US

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BELL, Michael, G. [US/US]; Apartment B, 9436 Knights Bridge, Indianapolis, IN 46240 (US). CROWELL, Thomas, A. [US/US]; 5871 Broadway Street, Indianapolis, IN 46220 (US). EVRARD, Deborah, A. [US/US]; 4639 Aerie Lane, Indianapolis, IN 46254 (US). MATTHEWS, Donald, P. [US/US]; 7736 Wawasee Drive, Indianapolis, IN 46250 (US). MCDONALD, John, H., III [US/US]; 433 Portsmouth Court, Carmel, IN 46032 (US). RITO, Christopher, J. [US/US]; 581 Arlington, Mooresville, IN 46158 (US). SHUKER, Anthony, J. [GB/US]; 2809 Sunnyfield Court, Indianapolis, IN 46208 (US). WINTER, Mark, A. [US/US]; 4733 Kessler View Drive, Indianapolis, IN 46220 (US).

(74) Agents: JONES, Joseph, A. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: SELECTIVE β_3 ADRENERGIC AGONISTS

(57) Abstract

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β_3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating Type II diabetes, comprising administering to a patient in need thereof compounds of formula (I).



(I)